Login / Signup

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.

Raphael MicheroliChristoph TellenbachAlmut SchererKristina BürkiKarin NiedermanMichael J NissenPascal ZuffereyPascale ExerBurkhard MöllerDiego KyburzAdrian Ciurea
Published in: Annals of the rheumatic diseases (2020)
Our data suggest a comparable effectiveness of SEC versus an alternative TNFi after prior TNFi exposure.
Keyphrases
  • rheumatoid arthritis
  • ankylosing spondylitis
  • randomized controlled trial
  • systematic review
  • disease activity
  • electronic health record
  • big data
  • quality improvement
  • artificial intelligence